Series G Preferred Shares-Company Option Sample Clauses

Series G Preferred Shares-Company Option. If on or ---------------------------------------- prior to October 1, 2001 the Company or one of its affiliates receives a written notice from the United States Food and Drug Administration (the "FDA") that its LaserScan LSX(R) excimer laser system has been approved or is approvable by the FDA to treat myopic astigmatism (the "Astigmatism Approval") the Company will publicly announce the receipt of the Astigmatism Approval within three (3) business days after the Company's receipt of the Astigmatism Approval (the date of such announcement shall be referred to as the "Astigmatism Approval Announcement Date"). Subject to the terms of this Section 1(d), for the ten (10) day period immediately following the Astigmatism Approval Announcement Date (such ten (10) day period shall be referred to as the "Company Option Period") the Company may elect at the Company's sole option (the "Company Option") to sell (and if the Company so elects such election shall be irrevocable and the Buyers will be obligated to purchase) 800,000 shares of the Series G Preferred Stock in the respective percentages set forth opposite each Buyer's name on the Schedule of Buyers (the "Company Additional Closing"). The per share purchase price for the Series G Preferred Shares shall be $2.50 or an aggregate purchase price of $2,000,000. The Company shall exercise the Company Option by providing written notice to Buyers pursuant to Section 9(f) (the "Company Notice") stating that the Company is exercising the Company Option and setting a closing date for the Company Additional Closing, provided that such Company Additional Closing must occur no sooner than five (5) days and no later than ten (10) days following the date of the Company Notice. Notwithstanding the foregoing, the Company will not have the ability to exercise the Company Option and the Company Option shall have no force or effect if the average VWAP (as defined below) for the Common Stock for the three trading days immediately prior to the date on which the Company exercises the Company Option (such three-day period referred to as the "Calculation Period") is less than $2.75 per share; provided that if the Astigmatism Approval Announcement Date falls within the Calculation Period, the Astigmatism Approval Announcement Date shall be excluded from the Calculation Period and the next available trading day not otherwise falling within the Calculation Period shall be included in the Calculation Period. The Company Option shall expire...
AutoNDA by SimpleDocs

Related to Series G Preferred Shares-Company Option

  • Series A Preferred Stock On the Closing Date, each Subscriber shall purchase and the Company shall sell to each such Subscriber, the number of shares of Preferred Stock designated on such Subscriber’s signature page hereto for such Subscriber’s Purchase Price indicated thereon.

  • Series C Preferred Stock The holders of outstanding shares of Series C Preferred Stock shall be entitled to receive dividends, when and as declared by the Board of Directors, out of any assets at the time legally available therefor, at the Dividend Rate specified for such shares of Preferred Stock payable in preference and priority to any declaration or payment of any distribution on Series A Preferred Stock, Series B Preferred Stock or Common Stock of the Corporation other than a dividend payable solely in Common Stock. No distributions shall be made with respect to the Series A Preferred Stock, Series B Preferred Stock or Common Stock during any fiscal year of the Corporation, other than dividends on the Common Stock payable solely in Common Stock, until all dividends at the applicable Dividend Rate on the Series C Preferred Stock have been declared and paid or set apart for payment to the holders of Series C Preferred Stock. The right to receive dividends on shares of Series C Preferred Stock shall not be cumulative, and no right to such dividends shall accrue to holders of Series C Preferred Stock by reason of the fact that dividends on said shares are not declared or paid in any year.

  • Series B Preferred Stock Section 1.2(d)......................... 5 Shares............................ Section 3.2(a).........................

  • Preferred Shares Notwithstanding Section 11.4.1, for the purpose of any computation hereunder, the "current per share market price" of the Preferred Shares shall be determined in the same manner as set forth above in Section 11.4.1 (other than the last sentence thereof). If the current per share market price of the Preferred Shares cannot be determined in the manner described in Section 11.4.1, the "current per share market price" of the Preferred Shares shall be conclusively deemed to be an amount equal to 100 (as such number may be appropriately adjusted for such events as stock splits, stock dividends and recapitalizations with respect to the Common Shares occurring after the date of this Agreement) multiplied by the current per share market price of the Common Shares (as determined pursuant to Section 11.4.1). If neither the Common Shares nor the Preferred Shares are publicly held or so listed or traded, or if on any such date neither the Common Shares nor the Preferred Shares are so quoted and no such market maker is making a market in either the Common Shares or the Preferred Shares, "current per share market price" of the Preferred Shares shall mean the fair value per share as determined in good faith by the Board of Directors of the Company, or, if at the time of such determination there is an Acquiring Person, by a nationally recognized investment banking firm selected by the Board of Directors of the Company, which shall have the duty to make such determination in a reasonable and objective manner, which determination shall be described in a statement filed with the Rights Agent and shall be conclusive for all purposes. For purposes of this Agreement, the "current per share market price" of one one-hundredth of a Preferred Share shall be equal to the "current per share market price" of one Preferred Share divided by 100.

  • Common Shares 4 Company...................................................................................... 4

  • Stock Warrants Subject to Board approval, Executive shall be granted stock warrants (the "Two Million Warrants") to purchase an aggregate of Two Million (2,000,000) shares of common stock of the Company. The Two Million Warrants are deemed to be of record as of January 1, 2007. The Two Million Warrants shall be granted in accordance with, and subject to the following:

  • Purchase of Preferred Shares Subject to the terms and conditions set forth in this Agreement, at the Closing the Company shall issue and sell to each Purchaser, and each Purchaser shall, severally and not jointly, purchase from the Company, the number of Preferred Shares set forth below such Purchaser’s name on the signature page of this Agreement at a per Preferred Share price equal to the Purchase Price.

  • Parent Shares All outstanding Parent Shares, and all Parent Shares, which may be issued pursuant to this Agreement shall when issued in accordance with this Agreement be, duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights.

  • Series A Preferred Units (a) The authorized number of Series A Preferred Units shall be unlimited. Series A Preferred Units that are purchased or otherwise acquired by the Partnership shall be cancelled.

  • Merger Sub Common Stock At the Effective Time, each share of common stock, par value $0.01 per share, of Merger Sub (“Merger Sub Common Stock”) issued and outstanding immediately prior to the Effective Time shall be automatically converted into one fully paid and nonassessable share of common stock, par value $0.01 per share, of the Surviving Corporation.

Time is Money Join Law Insider Premium to draft better contracts faster.